Skip to main content
Home
Articles
Latest Issue
Issue Archive
Special Issues
Supplements
Categories
Conference Correspondent
ASH 2023 - CLL
SABCS 2023 - HR+/HER2- MBC
Web Exclusives
All Web Exclusives
Interview with the Innovators
Rapid Reactions
FDA Oncology Update
Videos
Press Releases
Gastrointestinal Cancer Monthly Minutes
For Authors
Author Guidelines
Symptom Management Overview
Letters to the Editor Instructions
Join Our Peer Review
Submit a Manuscript
About
About JHOP
Contact Us
Editorial Policies
Peer-Review Process
About the Editors
Editorial Board
Editorial Process
Advertising Policy
Advertise
Subscribe
Home
Articles
Latest Issue
Issue Archive
Special Issues
Supplements
Categories
Conference Correspondent
ASH 2023 - CLL
SABCS 2023 - HR+/HER2- MBC
Web Exclusives
All Web Exclusives
Interview with the Innovators
Rapid Reactions
FDA Oncology Update
Videos
Press Releases
Gastrointestinal Cancer Monthly Minutes
For Authors
Author Guidelines
Symptom Management Overview
Letters to the Editor Instructions
Join Our Peer Review
Submit a Manuscript
About
About JHOP
Contact Us
Editorial Policies
Peer-Review Process
About the Editors
Editorial Board
Editorial Process
Advertising Policy
Advertise
AACR & ASCO 2021 - Midyear Review
AACR & ASCO 2021 - Midyear Review
Atezolizumab versus Best Supportive Care After Adjuvant Chemotherapy for Resected NSCLC (IMpower010)
Read More
AACR & ASCO 2021 - Midyear Review
Four-Year Update from CheckMate-227 Study of Nivolumab plus Ipilimumab in Advanced NSCLC
Read More
AACR & ASCO 2021 - Midyear Review
Phase 1 Study of Telisotuzumab Vedotin in Patients with c-Met–Mutated Advanced NSCLC
Read More
AACR & ASCO 2021 - Midyear Review
Exciting New Data Presented on NSCLC at AACR 2021
David Spigel, MD
Read More
AACR & ASCO 2021 - Midyear Review
Phase 1 Trial of VS-6766, a Dual RAF-MEK Inhibitor, and Defactinib, an FAK Inhibitor
Read More
AACR & ASCO 2021 - Midyear Review
Phase 2 Study of D-0316 in Patients with Advanced NSCLC and EGFR T790M Mutation
Read More
AACR & ASCO 2021 - Midyear Review
Phase 2 Study of Osimertinib + Oleclumab in Progressive T790M-Negative EGFR-Mutated NSCLC
Read More
AACR & ASCO 2021 - Midyear Review
Safety Results of Phase 2 Study of Bintrafusp plus Chemotherapy in Advanced NSCLC (INTR@PID LUNG 024)
Read More
AACR & ASCO 2021 - Midyear Review
Randomized Phase 3 Study of Sintilimab versus Docetaxel in Advanced Squamous NSCLC (ORIENT-3)
Read More
AACR & ASCO 2021 - Midyear Review
Phase 3 Study of Tislelizumab Compared with Docetaxel in Advanced NSCLC (RATIONALE 303)
Read More
1
2
3
Page 2 of 3
Results 11 - 20 of 25